Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer (IClyCO)
In patients with an ovarian cancer, the treatment is currently based on surgery and chemotherapy.
The impact of chemotherapy on the expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated.
The long term goal is to give a rational to combine conventional treatment of ovarian cancer with immunotherapy based on Vgamma9Vdelta2 T cells.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||IClyCO Influence of Chemotherapy (Carboplatin and Taxol) on the ex Vivo Expansion and Functional Capacity of Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer|
The VGAMMA9VDELTA2 T cells will be isolated from peripheral blood mononuclear cells of patients with ovarian cancer.
|Estimated Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
Drug: Carboplatin and / or taxol chemotherapy
Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
Ovarian cancer is associated with a high mortality rate. Treatment of ovarian cancer is currently based on surgery and chemotherapy.
The first surgery is a radical surgical procedure aiming to achieve no residual disease. Patients who could not benefit from the first surgery may be offered neoadjuvant chemotherapy with a new surgical procedure after 3 or 6 chemotherapy cycles. Chemotherapy is currently based on Taxol and Carboplatin. Immunotherapy based on Vgamma9Vdelta2 T cells could provide a promising therapeutic strategy, however, the impact of chemotherapy on the expansion and functional abilities of Vgamma9Vdelta2 T cells has never been evaluated.
We want to study the effect of chemotherapy of ovarian cancer on Vgamma9Vdelta2 T cells rates in the peripheral blood of patients with ovarian cancer.
Functional abilities of the Vgamma9Vdelta2 T cells will be studied: expansion after chemotherapy and their cytotoxic abilities in an autologous context before or after chemotherapy.
The long term goal is to give a rational to combine conventional treatment of ovarian cancer with non-conventional treatment such as immunotherapy based on Vgamma9Vdelta2 T cells.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01606358
|Contact: Vincent Lavoué, MD||2 99 26 59 72 ext + firstname.lastname@example.org|
|CHU de RENNES||Not yet recruiting|
|Rennes, France, 35000|
|Contact: Vincent Lavoué, MD 2 99 26 59 72 ext + 33 email@example.com|
|Sub-Investigator: Jean Levêque, MD PhD|
|Sub-Investigator: Fabrice Foucher, MD|
|Sub-Investigator: Estelle Bauville, MD|
|Sub-Investigator: Sébastien Henno, MD|
|Sub-Investigator: Françoise Bouet, MD|
|Sub-Investigator: Véronique Catros, MD|
|Sub-Investigator: Florian Cabillic, MD|
|Study Chair:||Bruno Laviolle, MD PhD||Rennes University Hospital|